Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Up 7.0% in March

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 35,300 shares, a growth of 7.0% from the March 15th total of 33,000 shares. Based on an average trading volume of 39,200 shares, the short-interest ratio is presently 0.9 days. Approximately 0.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Aileron Therapeutics by 23.2% in the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after buying an additional 10,311 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Aileron Therapeutics during the 4th quarter worth approximately $48,000. Sigma Planning Corp acquired a new stake in shares of Aileron Therapeutics during the 4th quarter worth approximately $51,000. Renaissance Technologies LLC grew its holdings in shares of Aileron Therapeutics by 96.9% during the 2nd quarter. Renaissance Technologies LLC now owns 115,191 shares of the company’s stock worth $30,000 after purchasing an additional 56,691 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Aileron Therapeutics by 52.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock worth $38,000 after purchasing an additional 63,651 shares in the last quarter. 90.89% of the stock is owned by institutional investors.

Aileron Therapeutics Stock Performance

Shares of ALRN stock opened at $4.25 on Thursday. The stock’s 50 day simple moving average is $5.39 and its 200 day simple moving average is $3.59. The company has a market capitalization of $20.78 million, a price-to-earnings ratio of -1.26 and a beta of 2.22. Aileron Therapeutics has a twelve month low of $1.01 and a twelve month high of $7.12.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.